



Sponsored Seminars

Breakfast Seminar (SciGen Ltd.)
March 29th 8:00-9:00 B-2

Pre-S1/Pre-S2/S Hepatitis B Vaccination and Means to Bypass Non-response to Conventional Immunization Against Hepatitis B

Moderator: D Shouval (Israel)

Opening Address and Introduction
Daniel Shouval, Israel

New Means for Augmentation of Immunogenicity of Hepatitis B Vaccines
George Lau, Hong Kong

Immunogenicity of a Pre-S1/Pre-S2/S Hepatitis B Vaccine in Non-Responders to Conventional Vaccination: Results of a Multi-Center Study
Daniel Shouval, Israel

Dendritic Cell Based Approach to Overcome Non-responsiveness to HBV Vaccination
Sk Mohammad F Akbar, Japan

Discussion, Q&A

Luncheon Seminar (Roche)
March 29th 12:30-14:00 Annex

Moderators: P Marcellin (France), N Hayashi (Japan)

Welcome

Building on a Solid Foundation
Patrick Marcellin, France

Creating Something Unique
Customising Treatment to Improve Outcomes
Sam Lee, Canada

Creating Something Unique
Customising Treatment in Asian Patients
Namiki Izumi, Japan

Shaping the Future
The Introduction of New Molecules for HCV Treatment
Stefan Zeuzem, Germany

A Model of Success Summary
Patrick Marcellin, France

Satellite Seminar (Schering-Plough)
March 29th 16:00-17:30 Annex

Towards Better Treatment Outcome for Hepatitis C

Moderators: M Manns (Germany), C Trepo (France)

Optimizing Hepatitis C Treatment for Japanese Patients
Yoshiyasu Karino, Japan

Treatment Experience for Hepatitis C in Taiwan
Wan-Long Chuang, Taiwan

Latest Evidence for Advances in Hep C Treatment
Christian Trepo, France

New Hep C Treatment Horizon
Stefan Zeuzem, Germany

Breakfast Seminar (Bayer AG)
March 30th 8:00-9:00 Room C-1

Molecular Signalling in the Pathogenesis and Future Treatment of Advanced Hepatocellular Carcinoma

Introduction

HCC: Epidemiology and Classification

Understanding the Molecular Pathogenesis of HCC

HCC: Current Treatment and Future

Perspectives

Jordi Bruix, Spain

Discussion and Concluding Remarks

Luncheon Seminar (Minophagen Pharmaceutical Co., Ltd)
March 30th 12:00-13:30 Annex

**Moderators: B Wang (China)
M Omata (Japan)**

Hepatitis C Non-responders to Peg-interferon Plus Ribavirin-Defining Unmet Needs
Michael Manns, Germany

Study on the Target Genes Trans-regulated by Glycyrrhizin Using Suppression Subtractive Hybridization and cDNA Microarray Assays

Jun Cheng, China

Combination Treatment of Chronic Hepatitis B with Stronger Neo-Minophagen C and Lamivudine
Yu-Ming Wang, China

Luncheon Seminar (AJINOMOTO PHARMA CO., LTD.& SAMIL PHARM CO., LTD.)

March 30th 12:00-13:00 Room B-1

Moderators: DJ Suh (Korea), S Nishiguchi (Japan)

Effect of Oral Supplementation with BCAA during Radiotherapy in Patients with Liver Tumor; Double-Blind Randomized Placebo-controlled Study
Jinsil Seong, Korea

Long-term Outcome of BCAA Treatment in Liver Cirrhosis
Hisataka Moriwaki, Japan

Luncheon Seminar (SciClone Pharmaceuticals, Inc.)
March 30th 12:00-13:00 Room B-2

New Therapies in Liver Cancer and Hepatitis

Moderator: JD Sollano (Philippines)

Treatment of Hepatitis C Non-Responders Utilizing Therapy with Pegylated Interferon, Ribavirin, and Thymalfasin
Kenneth E Sherman, USA

Treatment of Hepatocellular Carcinoma with TACE plus Thymalfasin
Stuart C Gordon, USA

DC Bead: A New Treatment Option in TACE
Jordi Bruix, Spain

Parallel Oral Session Poster Session